← Retour à la une
États-Unis · Plateformes & données · Yahoo Finance

Aptevo Provides 3Q26 Business Update Highlighting Growing Momentum for Mipletamig and Reports Third Quarter Financial Results

Publié par Yahoo Finance · États-Unis il y a 8 h
ACCESS Newswire · Aptevo Therapeutics
ACCESS Newswire · Aptevo Therapeutics · Yahoo Finance

Résumé détaillé

(NASDAQ:APVO), a clinical-stage biotechnology company developing novel multispecific immuno-oncology therapeutics, today reported financial results for the quarter ended September 30, 2026, and highlighted new clinical findings supporting mipletamig's potential in frontline acute myeloid leukemia (AML), progress in optimizing treatment tolerability, and continued advancement of its next-generation cancer treatment…

Mipletamig achieves 79% remission rate in high-risk TP53-mutated AML, nearly double the published historical benchmark

Ten of 47 patients receiving mipletamig combination therapy advances to potentially curative stem cell transplantation

Refined priming-dose regimen significantly reduces infusion-related reactions, marking important tolerability advance

Aptevo advances next generation trispecifics toward human testing, expanding opportunities beyond AML

SEATTLE, WA / ACCESS Newswire / November 16, 2026 / Aptevo Therapeutics Inc. (NASDAQ:APVO), a clinical-stage biotechnology company developing novel multispecific immuno-oncology therapeutics, today reported financial results for the quarter ended September 30, 2026, and highlighted new clinical findings supporting mipletamig's potential in frontline acute myeloid leukemia (AML), progress in optimizing treatment tolerability, and continued advancement of its next-generation cancer treatment pipeline.

"We are entering an exciting period for Aptevo, with growing clinical evidence that reinforces our confidence in mipletamig and meaningful progress across our broader pipeline," said Jeff Lamothe, President and Chief Executive Officer of Aptevo. "We are seeing strong clinical activity in patients with some of the most difficult-to-treat forms of AML, patients advancing to potentially curative stem cell transplantation, and important improvements in tolerability. Each of these findings adds a new dimension to the mipletamig story and strengthens our conviction in its potential to become an important addition to frontline AML treatment.

*Clinical benefit includes complete remission (CR), complete remission with incomplete hematologic recovery (CRi), partial response (PR) and morphologic leukemia-free state (MLFS).

These results are encouraging because patients with TP53-mutated AML have historically had limited treatment success.

Début de l'article, extrait de Yahoo Finance. Pour lire la suite, ouvrez l'article chez le média.

Lire l'article complet sur Yahoo Finance Connectez-vous pour sauvegarder

MarketNews présente le titre et le résumé publiés par le média. L'article complet se lit sur le site de l'éditeur. (finance.yahoo.com)

À lire aussi